Furthermore, a study by Bai H et al. [39] suggested that chemotherapy might affect the EGFR mutation status of NSCLC patients, as tumors can display heterogeneity in their mutational profiles. This evidence concerns the gene EGFR and non-small cell lung carcinoma.